Insights

3 Top Biotech Stocks to Buy Right Now

Thanks to population growth and aging, the global pharmaceutical market is expected to grow from $1.3 trillion in 2020 to $1.6 trillion by 2025. This should translate into a bright future for well-positioned biotech stocks.
Let’s take a look at three pharma stocks to consider buying right now that could be great fits in a diversified dividend stock portfolio.
Image source: Getty Images.

1. Sanofi
The first stock to think about purchasing now is Sanofi (NASDAQ: SNY). The French drugmaker’s $139 billion market capitalization makes it the 10th biggest pharma stock in the world.
Thus, it’s not surprising that the company’s portfolio contained five blockbuster drug franchises and two blockbuster vaccine franchises in 2021. In combination with a drug pipeline of 91 projects at different stages of development, this explains why analysts anticipate Sanofi will generate 10.3% annual earnings growth over the next five years. For context, this is significantly higher than the five-year industry average of 7%. 
And Sanofi’s far superior growth prospects can be acquired by investors at a forward price-to-earnings (P/E) ratio of 11.6. This is essentially in line with the industry average of 11.3, which means that Sanofi is a growth stock that’s also priced like a value stock. And if that wasn’t enough, the stock offers income investors a safe, market-trouncing 3.6% yield. This makes Sanofi an interesting buy for every type of investor. 
2. Pfizer
The second stock to contemplate buying right now is Pfizer (NYSE: PFE). With a $281 billion market cap, the New York-based drugmaker is the second-largest pharma stock in the world.
Pfizer is best-known for its blockbuster COVID-19 vaccine called Comirnaty and antiviral pill named Paxlovid. But Pfizer had eight other blockbuster franchises in 2021 like the anticoagulant co-owned with Bristol Myers Squibb called Eliquis. That’s why it would be unfair to label Pfizer as merely a COVID stock.
Thanks to the stock’s strong drug portfolio and pipeline of 96 projects at varying developmental phases, Pfizer should deliver robust earnings growth to its shareholders in the years ahead. 
Pfizer also provides investors with a market-topping 3.3% yield. And with the stock’s payout ratio set to be 25.2% in 2022, Pfizer has plenty of room to keep growing its dividend. Best of all, the stock is trading at a forward P/E ratio of just 8.7. That’s why Pfizer appears to be an excellent pick for income investors. 
3. AstraZeneca
The third stock to consider buying now is AstraZeneca (NASDAQ: AZN). The British drugmaker’s $205 billion market cap makes it the seventh-biggest pharma stock in the world.
AstraZeneca’s portfolio consisted of 12 blockbuster drugs as well as its blockbuster COVID-19 vaccine called Vaxzevria. And with 183 active projects in its drug pipeline, the company should have no problem building on its status as a mega-cap pharma stock going forward. This is why analysts are predicting that AstraZeneca will produce 15.4% annual earnings growth through the next five years.
Even though AstraZeneca’s annual earnings growth potential is more than double the industry average, the stock is trading at a forward P/E ratio of just 13. Throw in AstraZeneca’s market-besting 2.2% yield, and the stock looks like a no-brainer buy for long-term investors to build wealth.
Kody Kester has positions in Bristol Myers Squibb and Pfizer. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy. –

Thanks to population growth and aging, the global pharmaceutical market is expected to grow from $1.3 trillion in 2020 to $1.6 trillion by 2025. This should translate into a bright future for well-positioned biotech stocks.

Let’s take a look at three pharma stocks to consider buying right now that could be great fits in a diversified dividend stock portfolio.

Image source: Getty Images.

1. Sanofi

The first stock to think about purchasing now is Sanofi (NASDAQ: SNY). The French drugmaker’s $139 billion market capitalization makes it the 10th biggest pharma stock in the world.

Thus, it’s not surprising that the company’s portfolio contained five blockbuster drug franchises and two blockbuster vaccine franchises in 2021. In combination with a drug pipeline of 91 projects at different stages of development, this explains why analysts anticipate Sanofi will generate 10.3% annual earnings growth over the next five years. For context, this is significantly higher than the five-year industry average of 7%. 

And Sanofi’s far superior growth prospects can be acquired by investors at a forward price-to-earnings (P/E) ratio of 11.6. This is essentially in line with the industry average of 11.3, which means that Sanofi is a growth stock that’s also priced like a value stock. And if that wasn’t enough, the stock offers income investors a safe, market-trouncing 3.6% yield. This makes Sanofi an interesting buy for every type of investor

2. Pfizer

The second stock to contemplate buying right now is Pfizer (NYSE: PFE). With a $281 billion market cap, the New York-based drugmaker is the second-largest pharma stock in the world.

Pfizer is best-known for its blockbuster COVID-19 vaccine called Comirnaty and antiviral pill named Paxlovid. But Pfizer had eight other blockbuster franchises in 2021 like the anticoagulant co-owned with Bristol Myers Squibb called Eliquis. That’s why it would be unfair to label Pfizer as merely a COVID stock.

Thanks to the stock’s strong drug portfolio and pipeline of 96 projects at varying developmental phases, Pfizer should deliver robust earnings growth to its shareholders in the years ahead. 

Pfizer also provides investors with a market-topping 3.3% yield. And with the stock’s payout ratio set to be 25.2% in 2022, Pfizer has plenty of room to keep growing its dividend. Best of all, the stock is trading at a forward P/E ratio of just 8.7. That’s why Pfizer appears to be an excellent pick for income investors

3. AstraZeneca

The third stock to consider buying now is AstraZeneca (NASDAQ: AZN). The British drugmaker’s $205 billion market cap makes it the seventh-biggest pharma stock in the world.

AstraZeneca’s portfolio consisted of 12 blockbuster drugs as well as its blockbuster COVID-19 vaccine called Vaxzevria. And with 183 active projects in its drug pipeline, the company should have no problem building on its status as a mega-cap pharma stock going forward. This is why analysts are predicting that AstraZeneca will produce 15.4% annual earnings growth through the next five years.

Even though AstraZeneca’s annual earnings growth potential is more than double the industry average, the stock is trading at a forward P/E ratio of just 13. Throw in AstraZeneca’s market-besting 2.2% yield, and the stock looks like a no-brainer buy for long-term investors to build wealth.

Kody Kester has positions in Bristol Myers Squibb and Pfizer. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!